AGÕæÈ˹ٷ½

Aura Biosciences is a clinical-stage biotech developing Virus-Like Drug Conjugates; its lead candidate bel-sar is in a global Phase 3 CoMpass trial for early choroidal melanoma and in trials for choroidal metastases and bladder cancer. In a Phase 2 cohort of Phase 3-eligible patients, bel-sar achieved an 80% tumor control rate (8 of 10) and 90% visual acuity preservation, with a favorable safety profile; the company reported positive Phase 1 NMIBC data in March 2025 and is advancing a Phase 1b/2 NMIBC program.

On the balance sheet, Aura held $107.4M cash and $69.9M marketable securities (total $177.3M) as of June 30, 2025, received $69.9M net proceeds from a May 16, 2025 follow-on offering, and stated this funding is expected to support operations into the first half of 2027. The company reported a $54.5M net loss for the six months ended June 30, 2025 and an accumulated deficit of $428.7M, reflecting continued high R&D investment.

Aura Biosciences (AURA) furnished a press release announcing its financial results for the quarter ended June 30, 2025 and filed an updated corporate presentation as Exhibit 99.2. The press release is furnished and explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act; the corporate presentation is filed for purposes of Section 18. The company identifies itself as an emerging growth company and notes its common stock trades on The Nasdaq Global Market.

The filing includes a broad cautionary statement of forward-looking items, covering R&D timing and costs, preclinical and clinical trials, manufacturing, third-party collaborations, commercialization, funding and regulatory approvals, market size, and an expected cash runway into the first half of 2027.

Aura Biosciences (AURA) Form 4: Director Sapna Srivastava reported new equity awards dated 17 June 2025.

• 13,000 restricted stock units (RSUs) were granted at no cost; they vest on the earlier of 17 June 2026 or the next annual shareholder meeting, contingent on continued service.
• 17,000 stock options were issued with a $6.18 exercise price, identical vesting trigger, and an expiration date of 17 June 2035.

Following the transaction, Srivastava directly owns 23,500 common shares and 17,000 options. No shares were sold, and the awards constitute routine director compensation that modestly increases ownership alignment without immediate cash impact.

Form 4 filing overview � Aura Biosciences, Inc. (AURA)

On 06/18/2025, Aura Biosciences filed a Form 4 reporting insider transactions by director David Michael Johnson. On 06/17/2025, the reporting person received two equity awards under the company’s 2021 Stock Option and Incentive Plan:

• 13,000 Restricted Stock Units (RSUs) â€� issued at no cost; each RSU converts 1:1 into common shares. Vesting occurs in full on the earlier of 17 Jun 2026 or the next annual shareholder meeting, contingent on continued service.
• 17,000 stock options â€� exercise price $6.18, same vesting schedule as the RSUs, expiring 17 Jun 2035.

Post-transaction ownership reported:

• Direct: 179,167 common shares
• Indirect: 289,672 shares held through two irrevocable trusts (75,000 each) and Velocity Capital Management LLC (139,672), entities where Johnson exercises trustee or sole-member control.
• Total beneficial ownership: 468,839 shares.

The filing indicates acquisitions only; no dispositions were reported. The grants reinforce insider alignment through additional unvested equity that will mature within roughly one year, providing potential signaling value to investors regarding management’s confidence in the company’s prospects.

Form 4 overview: On 17 June 2025, Aura Biosciences (AURA) director Antony C. Mattessich reported equity-based awards that increase his direct ownership in the company.

• Restricted stock units: 13,000 RSUs were granted at no cost. The units convert 1-for-1 into common shares and vest in full on the earlier of 17 June 2026 or the next annual shareholder meeting, contingent on continued service.
• Stock options: 17,000 options with a US$6.18 exercise price were awarded on the same date. The options vest in full on the same schedule and expire 17 June 2035.
• Post-transaction holding: Mattessich now directly owns 23,500 common shares (includes previously held shares plus the new RSUs).

No open-market purchases or sales occurred; the filing reflects routine director equity compensation aligned with Aura’s 2021 Stock Option and Incentive Plan.

On 17 June 2025 Aura Biosciences, Inc. (Nasdaq: AURA) held its 2025 Annual Meeting of Stockholders, as reported in the Form 8-K filed 18 June 2025 under Item 5.07.

Participation: 38,863,371 common shares—or 77.3 % of the 50,268,758 shares entitled to vote—were present or represented by proxy.

Proposal 1 � Election of Class I Directors (terms through 2028)

• Elisabet de los Pinos, Ph.D.: 28,961,014 for; 985,262 withheld; 8,917,095 broker non-votes
• Giovanni Mariggi, Ph.D.: 29,179,073 for; 767,203 withheld; 8,917,095 broker non-votes

Both nominees were duly elected.

Proposal 2 � Ratification of Independent Auditor

• Ernst & Young LLP ratified for fiscal year ending 31 Dec 2025 with 38,623,566 for; 232,989 against; 6,816 abstentions; zero broker non-votes.

No additional matters were submitted. The filing contains no financial performance metrics, guidance, or transactional disclosures; therefore the event is considered routine corporate governance with limited immediate financial impact.